BridgeBio Advances Oral Infigratinib Toward Achondroplasia Launch
PALO ALTO, Calif. — September 9, 2026 BridgeBio Pharma, Inc. presented new exploratory analyses from the Phase 3 PROPEL...
pediatric endocrinology
Advertisement
Neurocrine Reports Two-Year CRENESSITY Data Showing Improved Growth in Pediatric CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has presented new two-year data from its Phase 3 CAHtalyst® Pediatric study,...
MannKind Gains FDA Approval for Afrezza in Pediatric Diabetes
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 MannKind Corporation announced that the U.S. Food and Drug Administration...
Foresee Pharmaceuticals Reports Positive CPP Phase 3 Data
TAIPEI, Taiwan, May 27, 2026 Foresee Pharmaceuticals has announced the successful completion of its Casppian Phase 3 clinical trial...
Ascendis Pharma Reports Positive Phase 2 Growth Data
COPENHAGEN, Denmark, March 17, 2026 Ascendis Pharma A/S announced positive Week 52 topline results from its Phase 2 New...
Advertisement
